This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and controls without pancreatic disease. This study aims to establish a diagnostic prediction model by using elastase 1, common clinical serological examinations, and imaging examinations including endoscopic ultrasonography (EUS), and to explore the diagnostic ability of the model in the high-risk population of PDAC. Besides, the investigators search for new biomarkers by multi-omics studies of serum and pancreatic tissues to further improve the diagnostic performance of this model. In conclusion, this study seeks a robust diagnostic prediction model to diagnose PDAC, especially early resectable PDAC.
Study Type
OBSERVATIONAL
Enrollment
2,100
Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
Ning Zhong
Jinan, Shandong, China
RECRUITINGThe diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)
The diagnostic value of diagnostic model in diagnosing PDAC, especially early resectable PDAC.
Time frame: 2 years
The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)
The diagnostic value of diagnostic model versus EUS or other imaging examinations combined with diagnostic model in diagnosing PDAC.
Time frame: 2 years
The content of elastase 1
The content of elastase-1 in cystic fluid and serum are measured (units: ng/dl)
Time frame: 2 years
The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)
The ability of diagnostic models, multi-omics novel tumor markers, and common tumor markers to distinguish PDAC, benign pancreatic disease, borderline malignant disease, patients with abnormally elevated CA199, and controls without pancreatic disease.
Time frame: 2 years
The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)
The diagnostic value of the diagnostic model, new tumor markers of multi-omics, and the common tumor markers to distinguish pancreatic tumors of different sites and sizes.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.